Research Use Only
HAUZ Research supplies compounds strictly for in-vitro laboratory use. Please confirm each statement before entering the site.
By entering, you agree to our Terms of Service.
Leave siteThe FDA Pharmacy Compounding Advisory Committee voted narrowly in July 2026 to recommend six peptides including BPC-157, KPV, and TB-500 for addition to the 503A Bulk Drug Substances List, marking a pivotal moment in peptide regulatory research.
Harvard professor David Sinclair’s lab has demonstrated that aging is not simply wear and tear — it is an information problem. In 2026, the FDA cleared the first human trial of cellular reprogramming technology. Here is what that means for longevity research, and how peptides fit into the picture.
The 503A Bulks List is a regulatory designation that allows licensed compounding pharmacies to prepare substances for individual patients without FDA approval. Understanding this pathway is essential for researchers tracking the evolving legal status of peptides like BPC-157, KPV, and TB-500.
The research peptide market has undergone a significant consolidation in 2025–2026. The closure of Peptide Sciences, FDA enforcement actions against multiple vendors, and new regulatory scrutiny have reduced the number of active suppliers while raising the bar for quality documentation and compliance.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protein found in the gastric mucosa. It has been studied extensively in preclinical models for tissue repair, gut lining integrity, tendon and ligament healing, and inflammatory pathway modulation. This guide covers everything a researcher needs to know about sourcing, verifying, and studying BPC-157.
TB-500 is the name most often used for a synthetic version of Thymosin Beta-4 (Tβ4), an actin-binding protein found in almost every cell. Preclinical research has examined its role in cell migration, angiogenesis and tissue repair.
GHK-Cu (Glycine-Histidine-Lysine Copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma. It has been studied extensively for its role in wound healing, collagen synthesis regulation, and anti-inflammatory signaling in preclinical and in vitro models.
KPV (Lys-Pro-Val) is a synthetic tripeptide corresponding to the C-terminal amino acids 11-13 of alpha-melanocyte stimulating hormone (α-MSH). It has been studied in preclinical models for its anti-inflammatory properties and potential role in gut barrier function, and was among the compounds reviewed by the FDA’s Pharmacy Compounding Advisory Committee in July 2026.
KLOW is a proprietary research blend developed by HAUZ Research combining four well-characterized peptides: BPC-157 (10mg), TB-500 (10mg), GHK-Cu (50mg), and KPV (10mg). Each component has been independently studied for tissue repair, anti-inflammatory, or regenerative properties, and the blend is designed for researchers studying multi-pathway approaches to tissue biology.
The BPC-157/TB-500 research blend combines BPC-157 and TB-500 (synthetic thymosin beta-4) in a single lyophilized preparation. Both have been studied for tissue repair in preclinical models, through different pathways.
News & Updates
Your cart is currently empty!
News & Updates
Subscribe to the latest updates and news.
Notifications